Founder & Board Chairman, Endeavor Biomedicines
John Hood is the founder or co-founder of Impact Biomedicines, Endeavor Biomedicines, Neuronomix and Samumed. Currently John is the founder and Chairman of the Board of Endeavor Biomedicines, a San Diego biotechnology company developing therapies for oncology and idiopathic pulmonary fibrosis, Founder of Neuronomix, board member of Micelle and Vice Chair of the Moore’s Cancer Center. Most recently he was the Founder and Chief Executive Officer of Impact Biomedicines, a company that was acquired for up to $7 billion by Celgene in 2018. Prior to founding Impact, Dr. Hood was the Co-Founder and Chief Scientific Officer of Samumed, a pharmaceutical company focused on advancing regenerative medicine and oncology therapies. Prior to that, Dr. Hood was Director of Research and co-inventor of fedratinib at TargeGen, Inc., (subsequently acquired by Sanofi SA), where he led a team identifying small molecule kinase inhibitors for the treatment of eye diseases and cancer. He is an inventor on 100+ patents and author on 50+ scientific articles. Dr. Hood obtained a Ph.D. in medical physiology and B.S. in biochemistry from Texas A&M University.